Search for European Projects

11 European Projects Found

Searched on 125080 European Projects

 FINISHED 

European AIDS Vaccine Initiative 2020 (EAVI2020)

Start date: Nov 1, 2015, End date: Oct 31, 2020,

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradicati ...
Read Project

 27

 FINISHED 

Common Oncogenic Mechanisms in Multi-Partner Translocation Families in Acute Myeloid Leukemia (ONCOMECHAML)

Start date: Jun 1, 2015, End date: May 31, 2020,

Acute Myeloid Leukemia (AML) is the most frequent cancer of the blood system, with >80% mortality within 5 years of diagnosis. Straightforward clinical decisions are complicated by the genetic complexity of AML. In particular, fusion proteins arising from chromosomal aberrations are recurrently found in AML and often act as strong driver oncogenes. In “Multi-Partner Translocation” (MPT) families, ...
Read Project

 1

 FINISHED 

Advanced Regenerative and REStorative Therapies to combat corneal BLINDNESS (ARREST BLINDNESS)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

Over 30 million Europeans are blind or visually impaired, leading to reduced quality of life and a tremendous loss of productivity in society. Corneal blindness is the second largest cause of blindness globally and while treatable, millions remain unnecessarily blind due to issues of access to transplantable tissue, lack of standardized treatments, and the lag in translating new regenerative medic ...
Read Project

 14

 FINISHED 

ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer (ALKATRAS)

Start date: Sep 1, 2015, End date: Aug 31, 2019,

This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; www.erialcl.net) is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with exc ...
Read Project

 13

 FINISHED 

Rational Bioactive Materials Design for Tissue Regeneration (BIODESIGN)

Start date: Jan 1, 2012, End date: Dec 31, 2016,

The development of functional materials for tissue regeneration is today mostly based on perceived and limited design criteria often using a single point approach with lengthy animal trials. The outcome after in-vitro and in-vivo evaluation is often disappointing resulting in a tedious iteration process. The main objective of this project is to achieve radical innovations in state-of-the-art bioma ...
Read Project

 21

 FINISHED 

Regime and Society in Eastern Europe (1956 - 1989). From Extended Reproduction to Social and Political Change (RESOCEA)

Start date: Jun 1, 2011, End date: May 31, 2016,

"The ambition of this project rests on the long-established tradition of the comparative politico-historical and interdisciplinary studies of the totalitarian regimes and on the theoretical efforts to elucidate the social dynamics and social change in Eastern Europe during the so called ""real socialism"". It will deal with the relations between regime and society in an attempt to highlight the gr ...
Read Project

 7

 FINISHED 

Enhancing the (cost-)effectiveness of diabetes self-management education: A comparative assessment of different educational approaches and conditions for successful implementation (DIABETES LITERACY)

Start date: Nov 1, 2012, End date: Dec 31, 2015,

The project aims to contribute to building the evidence base to increase the effectiveness of diabetes self-management education in the EU Member States, as part of a comprehensive diabetes strategy at EU level. To that effect, it will perform a systematic and comparative content analysis of the national diabetes strategies and frameworks across the 27 EU MS, establish a compendium of diabetes sel ...
Read Project

 9

 FINISHED 

Adopting Hospital Based Health Technology Assessment in EU (AdHopHTA)

Start date: Sep 1, 2012, End date: Nov 30, 2015,

The use of HTA as a part of the decision-making process at national, regional, and international levels has evolved considerably over the past 35 years. However, still an important number of good-value innovative HTs never reach clinical practice while, in many instances, others with no significant added value actually do. This situation can be effectively overcome by approaching HTA at hospital l ...
Read Project

 11

 FINISHED 

Biomimetic and Biomineralized Magnetic Nanoparticles for Magnetic Resonance Imaging (Bio2MaN4MRI)

Start date: Sep 1, 2011, End date: Aug 31, 2014,

Nanoscience and nanotechnology are currently revolutionizing sectors such as medicine, information technologies, environmental or materials sciences, and creating new opportunities for our societies. In this context, magnetic nanoparticles (MNP) are key components to the development of novel nano- and biotechnologies. Magnetosomes are unique hybrid magnetic MNP produced by magnetotactic bacteria ( ...
Read Project

 8

 FINISHED 

Angiogenesis-inducing Bioactive and Bioresponsive Scaffolds in Tissue Enginering (AngioScaff)

Start date: Dec 1, 2008, End date: Nov 30, 2012,

Angiogenesis underlies almost all biological processes of morphogenesis, including those in tissue repair and regeneration. Physiological angiogenesis is controlled by a complex interplay between cells and their environment: the extracellular matrix (ECM) provides signaling via numerous ECM adhesion molecules and growth factors bound to ECM polysaccharide components; and cells locally degrade and ...
Read Project

 33

 FINISHED 

Establishment of a novel CML model using Multi-Hit technology (CMLMULTIHIT)

Start date: May 17, 2010, End date: May 16, 2012,

"The chronic phase of chronic myeloid leukaemia (CML) is characterized by the expression of the chimeric BCR-ABL gene, extended survival, and profligate growth of maturing granulocyte stemline. It provided the rationale for producing first imatinib and then a series of small molecules designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein, all of which can induce complete cyto ...
Read Project

 1